The extended multiplication of the chr 10q23.3 region may be expected to manifest as a clinically relevant increase in CYP2C8 expression, and the negative outcome of the disease (progression or exit) in the present study was assumed to be associated with CYP2C8 multiplication and the increased paclitaxel-metabolizing capacity of tumour cells rather than the multiplication of tumour suppressor genes presumed on the basis of genomic location in CYP2C8 surroundings. This evidence concerns the gene CYP2C8 and neoplasm.